Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 38Lung Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Neoplasms 16Uterine Cervical Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 10Carcinoma, Hepatocellular 10Sarcoma 9Rectal Neoplasms 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Neoplasm Metastasis 8Melanoma 8Lymphoma 8Glioblastoma 8Colorectal Neoplasms 8Brain Neoplasms 8Thyroid Neoplasms 7Stomach Neoplasms 7Solid Tumor 7Pancreatic Neoplasms 7Oropharyngeal Neoplasms 7Multiple Myeloma 7Head and Neck Neoplasms 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Breast Neoplasms, Male 6

Interventions

durvalumab 2alfatide II 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer NSCLC × Fluorodeoxyglucose F18 × Clear all
NCT06416852 2024-05-16

Clinical Study of 18F-Alfatide Injection PET/CT

Yantai LNC Biotechnology Singapore PTE. LTD.

Phase 3 Not yet recruiting
428 enrolled
Thoracic

Non-Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡